Highlights Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-03-17 pm EDT			5-day change	1st Jan Change
59.99 ^USD	+1.66%		-4.94%	+6.06%

Mar. 17	Perspective Therapeutics Starts Dosing New Cohort for Melanoma Tumor Treatment Therapy	MT
Mar. 14	CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation	RE

Highlights

CMS Announces Manufacturer Participation in Second Cycle of Medicare Drug Price Negotiation	Mar. 14	RE
Bristol-Myers Squibb Says EU Approves Breyanzi for Relapsed, Refractory Follicular Lymphoma	Mar. 14	MT
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of Car T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma	Mar. 14	CI
Bristol Myers Squibb To Report Results For First Quarter 2025 On April 24, 2025	Mar. 13	RE
Sector Update: Health Care	Mar. 11	MT
Deals of the day-Mergers and acquisitions	Mar. 11	RE
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Markets Recover Ahead of Economic Data	Mar. 11	MT
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million	Mar. 11	RE
2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers	Mar. 11	DJ
2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers	Mar. 11	DJ
2seventy Bio to be Acquired by Bristol Myers Squibb	Mar. 11	MT
2Seventy Bio Enters Into Agreement To Be Acquired By Bristol Myers Squibb at $5.00 Per Share	Mar. 10	RE
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million.	Mar. 10	CI
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis	Mar. 08	CI
Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer	Mar. 07	MT
Bristol Myers Squibb Receives European Commission Approval for Opdivo®? Plus Yervoy®? for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma	Mar. 07	CI
Novartis not panicking over potential US pharmaceutical tariffs, chairman says	Mar. 06	RE
Evotec Announces Key Progress In Neuroscience Collaboration With Bristol Myers Squibb	Mar. 04	RE
Bristol Myers Squibb Announces Dividend	Mar. 03	RE
Bristol-Myers Squibb Keeps Dividend at $0.62 a Share, Payable May 1 to Shareholders as of April 4	Mar. 03	MT
Bristol-Myers Squibb Company Announces Quarterly Dividend on Common Stock, Payable on May 1, 2025	Mar. 03	CI
Drugmaker Viatris forecasts weak 2025 results after import curbs on India plant	Feb. 27	RE
U.S. FDA Accepts Bristol Myers Squibb'S Supplemental BLA For Opdivo® Plus Yervoy®	Feb. 24	RE
BioArctic-Bristol Myers Squibb Alzheimer's Deal Clears US Regulatory Hurdle	Feb. 20	MT
Bioarctic's Global License Agreement with Bristol Myers Squibb for Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance and Closing	Feb. 20	CI

51aa09c1dfe356cb2a3531c8ebfc4d4.HuHEvbg81FMSP1nZusipgIVde2iwEIIH6ng7-HwuYA8.Wqq00e0FpB1iWRyX0OWdzu4vDBzESdZwmR9VkwlkDz1Vs6ft0gymDHh5Og

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST